Travis Mickle, KemPharm CEO (via KemPharm)
Orphazyme agrees to sell itself, and its 'pipeline-in-a-product,' to KemPharm
Two months ago, Orphazyme enlisted the help of the Danish courts to help oversee a restructuring in the wake of trial failures, C-suite shakeups and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
